You searched for Health Technology Assessment (HTA) - Page 3 of 11 - OHE

We found for

Insight
February 2021

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?

Read more

Payment Models for Multi-Indication Therapies

Read more

© Photology1971/Shutterstock

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Read more

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Read more

Insight
January 2021

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

How is Quality of Life Measured for Health Technology Assessments?

Read more

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

Read more

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Read more

© Mitrovix

News
December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Insight
December 2020

A NICE Wind of Change? The What and So What of the NICE Methods Consultation

Insight
October 2020

The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision

News
September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

News
August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

News
July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Past Event
April 2020

How Should the World Pay for a COVID-19 Vaccine?

01
02
03
04
05
06
07
00